EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A20 Facilitates Oxaliplatin Sensitivity in Colorectal Cancer Through Monoubiquitylation of IKK‐β

Fan Luo iD, Ting Yang iD, Jiaxin Cao, Qun Chen, Zhenhai Lu, Feiteng Lu, Chaozhuo Lin, Zengfei Xia, Yuanzhong Yang, Peng Li, Wenjuan Ma, Min Luo und 1 weitere

Advanced Science · 2026

DOI: 10.1002/advs.202514486 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, 2026. Verfasst von Fan Luo und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Intensive Care Unit, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis an…. Hauptthemen laut MEDLINE: Oxaliplatin, Colorectal Neoplasms, I-kappa B Kinase, Tumor Necrosis Factor alpha-Induced Protein 3. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, China Postdoctoral Science Foundation, Natural Science Foundation of Guangdong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The ubiquitin‐editing enzyme A20 is essential for maintaining inflammatory homeostasis, yet its role in chemoresistance remains unclear. To investigate how A20 regulates oxaliplatin resistance in colorectal cancer (CRC), with a focus on A20‐mediated IKK‐β monoubiquitylation at K163. A prospective, randomized Phase III study is conducted in patients with locally advanced CRC who received either oxaliplatin+capecitabine neoadjuvant chemoradiotherapy (oxaliplatin‐NACRT) or capecitabine‐only neoadjuvant chemoradiotherapy (non‐oxaliplatin‐NACRT). Preoperative biopsy and matched surgical specimens are evaluated by immunohistochemistry to determine A20's association with oxaliplatin response. In oxaliplatin‐NACRT group, patients achieving pathological complete response (pCR) displayed lower A20 expression than non‐pCR patients, whereas no difference is observed in non‐oxaliplatin‐NACRT group. Two additional independent cohorts confirmed A20 downregulation in human CRC tissues, and reduced A20 expression correlated with poorer survival and oxaliplatin resistance. Mechanistically, A20 monoubiquitylates IKK‐β via its fourth zinc‐finger domain, promoting IKK‐β degradation and suppressing NF‐κB nuclear translocation. A20 knockdown or expression of the IKK‐β K163R mutant induced oxaliplatin resistance in mouse xenografts. Clinically, A20 expression are negatively associated with IKK‐β and its downstream targets. A20 depletion promotes oxaliplatin resistance in CRC by stabilizing IKK‐β. the results uncover an essential role of the A20‐IKK‐β axis in oxaliplatin resistance of CRC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OxaliplatinColorectal NeoplasmsI-kappa B KinaseTumor Necrosis Factor alpha-Induced Protein 3HumansDrug Resistance, NeoplasmMaleAnimalsFemaleUbiquitinationMiceAntineoplastic AgentsMiddle Aged

Stichwörter der Autor:innen

A20IKK‐βchemoresistancecolorectal canceroxaliplatin

Substanzen

OxaliplatinI-kappa B KinaseTumor Necrosis Factor alpha-Induced Protein 3TNFAIP3 protein, humanAntineoplastic AgentsIKBKB protein, human

Autor:innen und Institutionen

  • Department of Intensive Care Unit, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, S…
  • Department of Clinical Research, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun…
  • Department of Anesthesiology, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Ya…
  • Department of Medical Oncology, Fujian Medical University Union Hospital, Fuzhou, China.
  • Department of Colorectal Surgery, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Su…
  • Department of Experimental Research, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer,…

ORCID-Profile: Fan Luo, Ting Yang

Förderung

  • National Natural Science Foundation of China
  • China Postdoctoral Science Foundation
  • Natural Science Foundation of Guangdong Province
  • Fundamental Research Funds for the Central Universities, Sun Yat-sen University
  • Young Talents Program of Sun Yat-sen University Cancer Center
  • Fostering Program for NSFC Young Applicants (Tulip Talent Training Program) of Sun Yat-sen University Cancer Center

Zitieren

APA

Luo, F., Yang, T., Cao, J., Chen, Q., Lu, Z., Lu, F., Lin, C., Xia, Z., Yang, Y., Li, P., Ma, W., Luo, M., & Zhang, R. (2026). A20 Facilitates Oxaliplatin Sensitivity in Colorectal Cancer Through Monoubiquitylation of IKK‐β. Advanced Science. https://doi.org/10.1002/advs.202514486

Vancouver

Luo F, Yang T, Cao J, Chen Q, Lu Z, Lu F, et al. A20 Facilitates Oxaliplatin Sensitivity in Colorectal Cancer Through Monoubiquitylation of IKK‐β. Advanced Science. 2026. doi:10.1002/advs.202514486

BibTeX
@article{Luo2026,
  author = {Luo, Fan and Yang, Ting and Cao, Jiaxin and Chen, Qun and Lu, Zhenhai and Lu, Feiteng and Lin, Chaozhuo and Xia, Zengfei and Yang, Yuanzhong and Li, Peng and Ma, Wenjuan and Luo, Min and Zhang, Rongxin},
  title = {A20 Facilitates Oxaliplatin Sensitivity in Colorectal Cancer Through Monoubiquitylation of IKK‐β},
  journal = {Advanced Science},
  year = {2026},
  doi = {10.1002/advs.202514486}
}
Kostenlos starten →